deutsche bank presentation & phase iii, page-7

Please note the following presented in our March update

About the Phase III Trial

"The Phase III Trial for CVacTM will be conducted on a 750 patient population in a double-blind, placebo-controlled study (randomized 1:1) of CVacs Standard of Care.

It will be conducted across multiple sites in Europe, US and Australia. This will include the world renowned Charite University Hospital in Berlin, Bonn University, both in Germany, Stanford Medical Centre in the United States and the Austin Hospital in Melbourne, Australia.

The trial will run concurrently with the Phase IIb Clinical Trial, which is currently underway, under the authority of US Food and Drug Administration.